Cube Pharmaceutical announced on the evening of April 14. Recently, the company received the “Drug Registration Certificate” for methylphenidate hydrochloride extended-release tablets approved and issued by the State Drug Administration. Methylphenidate hydrochloride extended-release tablets belong to the first class of psychotropic drugs and are mainly used clinically to treat attention deficit hyperactivity disorder. As of the date of this announcement, with the exception of our products, there is only one imported drug approval number for this product in China, and no other companies have entered the clinical research or registration process.

Cube Pharmaceutical announced on the evening of April 14. Recently, the company received the “Drug Registration Certificate” for methylphenidate hydrochloride extended-release tablets approved and issued by the State Drug Administration. Methylphenidate hydrochloride extended-release tablets belong to the first class of psychotropic drugs and are mainly used clinically to treat attention deficit hyperactivity disorder. As of the date of this announcement, with the exception of our products, there is only one imported drug approval number for this product in China, and no other companies have entered the clinical research or registration process.